ILLUMINA, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Illumina (ILMN) stock has risen 160% from its October 2025 low, defying broader market trends. The genomics company reported Q2 revenue of $1.16B, up 9.5% YoY, and raised full-year guidance. The stock is up 74.5% YTD and will be added to the S&P 500. Analysts note its strong technical performance and relative strength.
Several biotech stocks hit 52-week highs on September 16, 2026. BlossomHill Therapeutics rose 18% due to positive trial data. Adaptive Biotechnologies, Illumina, Ceribell, and Neogen also reached highs. Illumina will join the S&P 500 in September.
Biotech stocks BLSM, NEOG, ILMN, CBLL, and ADPT hit 52-week highs. BLSM rose 18% on positive trial data, NEOG grew 2% with Q4 revenue of $225M, ILMN reached $236 on 9.5% Q2 growth, CBLL hit $25.63 with Q2 revenue up 33%, and ADPT climbed 3% with full-year revenue forecast between $268M-$278M.
Over the past 7 days, AlphAI's AI scored 12 news stories mentioning ILMN (ILLUMINA, INC.). Coverage has skewed bullish: 9 bullish, 3 neutral, and 0 bearish.
Recent ILMN coverage spans market movers, earnings and financial news.
In the last 30 days, ILMN insiders filed 54 SEC Form 4 transactions — no purchases and 54 sales ($288.2M). The most active reporter was Meister Keith A. with 53 filings. 2% of those filings were made under pre-arranged Rule 10b5-1 plans.
Earnings beat and raised guidance suggest upside potential for ILMN, especially given its relative strength versus the biotech sector.
Listed as a peer; no fresh information on Illumina itself.
Strong revenue growth and upbeat guidance could sustain the rally.
ILMN may see modest inflows from index funds, supporting price.
Positive short-term momentum as the stock outperforms peers in a broad diagnostics rally.
AlphAI scores every news story that mentions ILMN with an AI model for sentiment and relevance, and aggregates insider trades from ILLUMINA, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Illumina (ILMN) stock has risen 160% from its October 2025 low, defying broader market trends. The genomics company reported Q2 revenue of $1.16B, up 9.5% YoY, and raised full-year guidance. The stock is up 74.5% YTD and will be added to the S&P 500. Analysts note its strong technical performance and relative strength.
3 min readSeveral biotech stocks hit 52-week highs on September 16, 2026. BlossomHill Therapeutics rose 18% due to positive trial data. Adaptive Biotechnologies, Illumina, Ceribell, and Neogen also reached highs. Illumina will join the S&P 500 in September.
2 min readBiotech stocks BLSM, NEOG, ILMN, CBLL, and ADPT hit 52-week highs. BLSM rose 18% on positive trial data, NEOG grew 2% with Q4 revenue of $225M, ILMN reached $236 on 9.5% Q2 growth, CBLL hit $25.63 with Q2 revenue up 33%, and ADPT climbed 3% with full-year revenue forecast between $268M-$278M.
3 min readVanguard S&P 500 ETF (VOO) will add Bloom Energy (BE), Illumina (ILMN), and another company, while removing Molson Coors (TAP), The Trade Desk (TTD), and Builders FirstSource (BLDR). BE's product revenue surged 215% due to AI demand, and ILMN raised EPS guidance. The changes have minimal impact on VOO's returns, as the fund is heavily concentrated in megacap stocks.
3 min readIllumina's stock rose 5.2% to $219.11 on Tuesday, part of a broader rally in the diagnostics and research sector. Peers like TMO, WST, and MEDP also gained between 3.9% and 4.2%. The move reflects sector-wide sentiment rather than company-specific news, with Illumina's market cap reaching $33.7B. Recent analyst activity shows modest bullishness, with one price target raised in the past week.
1 min readIllumina Inc. (ILMN) shares rose 7.15% on September 15, 2026, driven by positive analyst upgrades and upcoming S&P 500 inclusion. UBS raised its target to $260, citing revenue growth and margin expansion, while Argus set a $235 target. Q2 revenue was $1.16B with strong margins. Insider selling was noted but not seen as a fundamental change.
3 min readARK Invest, led by Cathie Wood, sold shares in multiple crypto-linked holdings, including ARKB, COIN, CRCL, and BMNR. The firm trimmed over 1.5% of its Bitcoin ETF (ARKB) positions. Bitcoin's price fell below $77,000, and retail sentiment remained bearish. Other tech stocks like AMZN, AMD, and SHOP were also reduced.
2 min readS&P Dow Jones Indices announced Bloom Energy, Illumina, and Everpure will join the S&P 500, replacing Molson Coors, The Trade Desk, and Builders FirstSource in the S&P SmallCap 600. The changes will take effect before the market opens later this quarter.
1 min readBarrington Research upgraded Copart (CPRT) to Outperform with a $40 target, while Freedom Broker upgraded IES Holdings (IESC) to Buy with a $440 target. CPRT closed at $30.75 and IESC at $319.52 on Thursday.
1 min readIllumina raised its full-year 2026 guidance, expecting revenue of $4.60B-$4.64B and EPS of $5.30-$5.40, citing strong clinical consumables growth and momentum in multiomics. The company also announced new leadership and partnerships. Analysts project revenue growth to $6B by 2030, with mixed stock ratings and an average price target of $207.21.
2 min read
